Image
 

Locate Available Clinical Trials

To view available Clinical Trial information choose from the list on the right or search using the fields below.

 

 

trial #
trial description
  • Alliance A031102
  • The purpose of this study is to compare the good and bad effects of using standard-doses of chemotherapy to using high-doses of chemotherapy. Both of these types of chemotherapy have been shown to shrink cancer when given as the second chemotherapy treatment, but it is not known whether one type is better than the other. This study will allow researchers to learn whether the high-dose chemotherapy is better, the same, or worse than the standard-dose chemotherapy.

  • Alliance A031501
  • The purpose of this study is to compare any good and bad effects of using a drug called MK-3475 (pembrolizumab) after the removal of your muscle invasive bladder cancer. MK-3475 is a drug that uses a person’s own immune system to treat cancer. This study will allow researchers to know whether treatment with MK-3475 is better, the same, or worse than the usual approach. To be better, the MK-3475 should increase life by 9 months or more, compared to observation alone. The use of MK-3475 could prevent your cancer from returning but it could also cause side effects. This immunotherapy drug, MK-3475, is already FDA-approved for use in other types of cancers, but for your type of cancer it is considered investigational.

  • CTSU AGCT1531
  • CTSU EA8143
  • CTSU EA8153
  • The purpose of this research study is to compare any good or bad effects of using the chemotherapy drug cabazitaxel (also known as Jevtana®) with the usual approach of the hormone based therapy abiraterone acetate (also known as Zytiga®) in combination with prednisone on patients with advanced prostate cancer that have already undergone treatment with hormone therapy and the chemotherapy drug docetaxel. In this research study, you will get either the standard of care combination of abiraterone acetate and prednisone, or you will get abiraterone acetate and prednisone in combination with the chemotherapy drug cabazitaxel.

     

  • NRG GU002
  • The purpose of this study is to compare any good and bad effects of using docetaxel along with the radiation therapy and hormone suppression therapy to using radiation and hormone suppression therapy alone in men with a high chance of prostate cancer recurrence after surgically removing the prostate.  Docetaxel is FDA-approved for prostate cancer that has spread and does not respond to hormone suppression. In this study, docetaxel is being used off-label. Off-label means that the FDA has not yet approved docetaxel for this type of prostate cancer that has not spread. The addition of docetaxel to the usual radiation and hormone suppression therapy could shrink your cancer or prevent it from returning but it could also cause side effects. This study will allow the researchers to know whether this different approach is better, the same, or worse than the usual approach.

  • NRG GU005
  • The purpose of this study is to compare any good and bad effects of using stereotactic body radiation therapy (SBRT), a technique that gives treatment in a shorter amount of time compared to the usual radiation therapy.

  • NRG GU006
  • NRG GU006
  • NRG/RTOG 0924
  • The purpose of this study is to compare the effects of hormone therapy and radiation therapy to the prostate gland and seminal vesicles with hormone therapy and radiation therapy to the whole pelvic body area for prostate cancer to find out which is better.

  • SWOG S1500
  • The purpose of this study is to compare three experimental drugs not approved by the FDA to treat advanced kidney cancer (crizotinib, cabozantinib and savolitinib) that block a protein called MET to the drug sunitinib which is currently a standard treatment to see if any of these drugs slow down tumor growth compared to sunitinib. Sunitinib is approved by the FDA for treating advanced kidney cancer, but not specifically for treating papillary kidney cancer. This study will allow researchers to know whether any of these drugs are better, the same, or worse than sunitinib. For any of the experimental drugs to be considered better, the experimental drug should increase life by four and a half months or more compared to the drug sunitinib.

  • SWOG S1602
  • SWOG S1605